Square Pharmaceuticals PLC, one of the country’s leading listed pharmaceutical companies, has reported a 21.54% year-on-year increase in earnings per share (EPS) for the first quarter ending September 30, 2025.
The company disclosed its unaudited financial statements for the July–September 2025 quarter following approval by its Board of Directors at a meeting held on Wednesday, November 12.
According to company sources, Square Pharmaceuticals’ consolidated EPS stood at Tk 8.35 for the quarter, compared to Tk 6.87 during the same period last year, reflecting solid growth in earnings.
As of September 30, 2025, the company’s net asset value per share (NAVPS) was reported at Tk 167.50, demonstrating continued financial strength and stability.
